[Cellular immune function influence on postoperative patients with hepatocellular carcinoma and the clinical effect of TILs treatment].
OBJECTIVE
To investigate the cellular immune function influence on postoperative patients with hepatocellular carcinoma (HCC) and clinical effect of TILs, rIL-2 and cyclophosphamide treatment.


METHODS
Eight postoperative HCC patients were treated with TILs, rIL-2 and cyclophosphamide. Six patients were infused from the hepatic artery, and the other 2 infused from the portal vein.


RESULTS
The IL-2 NK activity, Tsubsets, CD4(+)/CD8(+) level in the peripheral blood of all patients increased and the IL-6, TNF level of most patients decreased (P > 0.05, P < 0.01). For 6 - 18 month follow-up after management, 6 patients with radical tumor resection showed no recurrence. One patient having palliative resection showed no remnant tumor enlargement. One patient with increased TNF level for 8 IU died from hepatic failure 8 months after chemotherapy.


CONCLUSIONS
The TILs, rIL-2 and cyclophosphamide treatment of postoperative HCC patients is effective in improving antitumorgenic immune function, preventing tumor recurrence, and restraining remnant tumor growth.
Ba
M
M
Department of Hepatic Bili Pancreatic Surgery, First University Hospital, West-China University of Medical Sciences, Chengdu 610041.
He
S
S
Zhang
C
C
Wei
D
D
Zhao
Z
Z
D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000628:therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D007111:Immunity, Cellular / Q000502:physiology; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007376:Interleukin-2 / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000276:immunology / Q000628:therapy*; D016246:Lymphocytes, Tumor-Infiltrating / Q000637:transplantation*; D008297:Male; D008875:Middle Aged
D007376:Interleukin-2; D003520:Cyclophosphamide